The role of microneedle arrays in drug delivery and patient monitoring to prevent diabetes induced fibrosis

Emma McAlister; Melissa Kirkby; Juan Domínguez-Robles; Alejandro J. Paredes; Qonita Kurnia Anjani; Kurtis Moffatt; Lalitkumar K. Vora; Aaron R. J. Hutton; Peter E. McKenna; Eneko Larrañeta; Ryan F. Donnelly

doi:10.1016/j.addr.2021.06.002

The role of microneedle arrays in drug delivery and patient monitoring to prevent diabetes induced fibrosis

Emma McAlister, Melissa Kirkby, Juan Domínguez-Robles, Alejandro J. Paredes, Qonita Kurnia Anjani, Kurtis Moffatt, Lalitkumar K. Vora, Aaron R. J. Hutton, Peter E. McKenna, Eneko Larrañeta, Ryan F. Donnelly

Research output: Contribution to journal › Review article › peer-review

47 Citations (Scopus)

607 Downloads (Pure)

Abstract

Diabetes affects approximately 450 million adults globally. If not effectively managed, chronic hyperglycaemia causes tissue damage that can develop into fibrosis. Fibrosis leads to end-organ complications, failure of organ systems occurs, which can ultimately cause death. One strategy to tackle end-organ complications is to maintain normoglycaemia. Conventionally, insulin is administered subcutaneously. Whilst effective, this delivery route shows several limitations, including pain. The transdermal route is a favourable alternative. Microneedle (MN) arrays are minimally invasive and painless devices that can enhance transdermal drug delivery. Convincing evidence is provided on MN-mediated insulin delivery. MN arrays can also be used as a diagnostic tool and monitor glucose levels. Furthermore, sophisticated MN array-based systems that integrate glucose monitoring and drug delivery into a single device have been designed. Therefore, MN technology has potential to revolutionise diabetes management. This review describes the current applications of MN technology for diabetes management and how these could prevent diabetes induced fibrosis.

Original language	English
Article number	113825
Number of pages	29
Journal	Advanced Drug Delivery Reviews
Volume	175
Early online date	17 Jun 2021
DOIs	https://doi.org/10.1016/j.addr.2021.06.002
Publication status	Published - Aug 2021

Keywords

Diabetes
End-organ complications
Microneedle-mediated transdermal delivery
Minimally invasive devices
Insulin delivery systems
Glucose monitoring
Interstitial fluid

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.addr.2021.06.002Licence: Unspecified

The role of microneedle arrays in drug delivery and patient monitoring to prevent diabetes induced fibrosis
Copyright 2021 Elsevier. This manuscript is distributed under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.
Accepted author manuscript, 5.62 MBLicence: CC BY-NC-ND

Microarray patches for the delivery of the poorly soluble drug olanzapine
McKenna, P. (Author), Donnelly, R. (Supervisor), Larraneta Landa, E. (Supervisor) & Kearney, M.-C. (Supervisor), Jul 2022
Student thesis: Doctoral Thesis › Doctor of Philosophy
Transdermal delivery of heavy chain only antibody binding domains using hydrogel-forming microarray patches
Hutton, A. (Author), Donnelly, R. (Supervisor) & Scott, C. (Supervisor), Jul 2022
Student thesis: Doctoral Thesis › Doctor of Philosophy

Cite this

McAlister, E., Kirkby, M., Domínguez-Robles, J., Paredes, A. J., Anjani, Q. K., Moffatt, K., Vora, L. K., Hutton, A. R. J., McKenna, P. E., Larrañeta, E., & Donnelly, R. F. (2021). The role of microneedle arrays in drug delivery and patient monitoring to prevent diabetes induced fibrosis. Advanced Drug Delivery Reviews, 175, Article 113825. https://doi.org/10.1016/j.addr.2021.06.002

@article{a8d0d7f9ddd144a691d8dc6e6734d31e,

title = "The role of microneedle arrays in drug delivery and patient monitoring to prevent diabetes induced fibrosis",

abstract = "Diabetes affects approximately 450 million adults globally. If not effectively managed, chronic hyperglycaemia causes tissue damage that can develop into fibrosis. Fibrosis leads to end-organ complications, failure of organ systems occurs, which can ultimately cause death. One strategy to tackle end-organ complications is to maintain normoglycaemia. Conventionally, insulin is administered subcutaneously. Whilst effective, this delivery route shows several limitations, including pain. The transdermal route is a favourable alternative. Microneedle (MN) arrays are minimally invasive and painless devices that can enhance transdermal drug delivery. Convincing evidence is provided on MN-mediated insulin delivery. MN arrays can also be used as a diagnostic tool and monitor glucose levels. Furthermore, sophisticated MN array-based systems that integrate glucose monitoring and drug delivery into a single device have been designed. Therefore, MN technology has potential to revolutionise diabetes management. This review describes the current applications of MN technology for diabetes management and how these could prevent diabetes induced fibrosis.",

keywords = "Diabetes, End-organ complications, Microneedle-mediated transdermal delivery, Minimally invasive devices, Insulin delivery systems, Glucose monitoring, Interstitial fluid",

author = "Emma McAlister and Melissa Kirkby and Juan Dom{\'i}nguez-Robles and Paredes, {Alejandro J.} and Anjani, {Qonita Kurnia} and Kurtis Moffatt and Vora, {Lalitkumar K.} and Hutton, {Aaron R. J.} and McKenna, {Peter E.} and Eneko Larra{\~n}eta and Donnelly, {Ryan F.}",

year = "2021",

month = aug,

doi = "10.1016/j.addr.2021.06.002",

language = "English",

volume = "175",

journal = "Advanced Drug Delivery Reviews",

issn = "0169-409X",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - The role of microneedle arrays in drug delivery and patient monitoring to prevent diabetes induced fibrosis

AU - McAlister, Emma

AU - Kirkby, Melissa

AU - Domínguez-Robles, Juan

AU - Paredes, Alejandro J.

AU - Anjani, Qonita Kurnia

AU - Moffatt, Kurtis

AU - Vora, Lalitkumar K.

AU - Hutton, Aaron R. J.

AU - McKenna, Peter E.

AU - Larrañeta, Eneko

AU - Donnelly, Ryan F.

PY - 2021/8

Y1 - 2021/8

N2 - Diabetes affects approximately 450 million adults globally. If not effectively managed, chronic hyperglycaemia causes tissue damage that can develop into fibrosis. Fibrosis leads to end-organ complications, failure of organ systems occurs, which can ultimately cause death. One strategy to tackle end-organ complications is to maintain normoglycaemia. Conventionally, insulin is administered subcutaneously. Whilst effective, this delivery route shows several limitations, including pain. The transdermal route is a favourable alternative. Microneedle (MN) arrays are minimally invasive and painless devices that can enhance transdermal drug delivery. Convincing evidence is provided on MN-mediated insulin delivery. MN arrays can also be used as a diagnostic tool and monitor glucose levels. Furthermore, sophisticated MN array-based systems that integrate glucose monitoring and drug delivery into a single device have been designed. Therefore, MN technology has potential to revolutionise diabetes management. This review describes the current applications of MN technology for diabetes management and how these could prevent diabetes induced fibrosis.

AB - Diabetes affects approximately 450 million adults globally. If not effectively managed, chronic hyperglycaemia causes tissue damage that can develop into fibrosis. Fibrosis leads to end-organ complications, failure of organ systems occurs, which can ultimately cause death. One strategy to tackle end-organ complications is to maintain normoglycaemia. Conventionally, insulin is administered subcutaneously. Whilst effective, this delivery route shows several limitations, including pain. The transdermal route is a favourable alternative. Microneedle (MN) arrays are minimally invasive and painless devices that can enhance transdermal drug delivery. Convincing evidence is provided on MN-mediated insulin delivery. MN arrays can also be used as a diagnostic tool and monitor glucose levels. Furthermore, sophisticated MN array-based systems that integrate glucose monitoring and drug delivery into a single device have been designed. Therefore, MN technology has potential to revolutionise diabetes management. This review describes the current applications of MN technology for diabetes management and how these could prevent diabetes induced fibrosis.

KW - Diabetes

KW - End-organ complications

KW - Microneedle-mediated transdermal delivery

KW - Minimally invasive devices

KW - Insulin delivery systems

KW - Glucose monitoring

KW - Interstitial fluid

U2 - 10.1016/j.addr.2021.06.002

DO - 10.1016/j.addr.2021.06.002

M3 - Review article

SN - 0169-409X

VL - 175

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

M1 - 113825

ER -

The role of microneedle arrays in drug delivery and patient monitoring to prevent diabetes induced fibrosis

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Student theses

Microarray patches for the delivery of the poorly soluble drug olanzapine

Transdermal delivery of heavy chain only antibody binding domains using hydrogel-forming microarray patches

Cite this